Journal article icon

Journal article

Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.

Abstract:

BACKGROUND: Alemtuzumab (MabCampath, Campath-1H) is a lymphocyte-depleting monoclonal antibody increasingly used in renal transplantation. This article reports the long-term follow-up data from the first series of patients treated with alemtuzumab for biopsy-proven acute rejection (BPAR). METHODS: Fifteen patients were identified who had received alemtuzumab for BPAR between November 1991 and June 1994. Patient and allograft survival were compared with a control group consisting of 25 patient...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1097/tp.0b013e31819d3353

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Surgical Sciences
Role:
Author
Expand authors...
Journal:
Transplantation
Volume:
87
Issue:
7
Pages:
1092-1095
Publication date:
2009-04-01
DOI:
EISSN:
1534-6080
ISSN:
0041-1337
Source identifiers:
4725

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP